Literature DB >> 33260773

Modifying Adaptive Therapy to Enhance Competitive Suppression.

Elsa Hansen1, Andrew F Read1,2,3.   

Abstract

Adaptive therapy is a promising new approach to cancer treatment. It is designed to leverage competition between drug-sensitive and drug-resistant cells in order to suppress resistance and maintain tumor control for longer. Prompted by encouraging results from a recent pilot clinical trial, we evaluate the design of this initial test of adaptive therapy and identify three simple modifications that should improve performance. These modifications are designed to increase competition and are easy to implement. Using the mathematical model that supported the recent adaptive therapy trial, we show that the suggested modifications further delay time to tumor progression and also increase the range of patients who can benefit from adaptive therapy.

Entities:  

Keywords:  adaptive therapy; competition; resistance; treatment regimen

Year:  2020        PMID: 33260773     DOI: 10.3390/cancers12123556

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  3 in total

1.  In Silico Investigations of Multi-Drug Adaptive Therapy Protocols.

Authors:  Daniel S Thomas; Luis H Cisneros; Alexander R A Anderson; Carlo C Maley
Journal:  Cancers (Basel)       Date:  2022-05-30       Impact factor: 6.575

2.  Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?

Authors:  Juan Diaz-Colunga; Ramon Diaz-Uriarte
Journal:  PLoS Comput Biol       Date:  2021-12-21       Impact factor: 4.475

3.  The impact of the spatial heterogeneity of resistant cells and fibroblasts on treatment response.

Authors:  Masud M A; Jae-Young Kim; Cheol-Ho Pan; Eunjung Kim
Journal:  PLoS Comput Biol       Date:  2022-03-09       Impact factor: 4.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.